Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

NCT04335682 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT04335682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2021
Completion date
May 1, 2026
Enrollment
111 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, hormone sensitive prostate cancer, metastatic prostate cancer, non-metastatic prostate cancer, prostate cancer, prostate cancer metastatic